251 related articles for article (PubMed ID: 23026237)
1. Construction, expression, and characterization of an anti-tumor immunotoxin containing the human anti-c-Met single-chain antibody and PE38KDEL.
Liu Z; Feng Z; Zhu X; Xu W; Zhu J; Zhang X; Fan Z; Ji G
Immunol Lett; 2013 Jan; 149(1-2):30-40. PubMed ID: 23026237
[TBL] [Abstract][Full Text] [Related]
2. Phage display-based generation of novel internalizing antibody fragments for immunotoxin-based treatment of acute myeloid leukemia.
Fitting J; Blume T; Ten Haaf A; Blau W; Gattenlöhner S; Tur MK; Barth S
MAbs; 2015; 7(2):390-402. PubMed ID: 25760770
[TBL] [Abstract][Full Text] [Related]
3. Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells.
Tur MK; Huhn M; Thepen T; Stöcker M; Krohn R; Vogel S; Jost E; Osieka R; van de Winkel JG; Fischer R; Finnern R; Barth S
Cancer Res; 2003 Dec; 63(23):8414-9. PubMed ID: 14679004
[TBL] [Abstract][Full Text] [Related]
4. Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors.
Chandramohan V; Bao X; Kato Kaneko M; Kato Y; Keir ST; Szafranski SE; Kuan CT; Pastan IH; Bigner DD
Int J Cancer; 2013 May; 132(10):2339-48. PubMed ID: 23115013
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of a recombinant anti-prostate specific membrane antigen single-chain immunotoxin against prostate cancer.
Wolf P; Alt K; Wetterauer D; Bühler P; Gierschner D; Katzenwadel A; Wetterauer U; Elsässer-Beile U
J Immunother; 2010 Apr; 33(3):262-71. PubMed ID: 20445346
[TBL] [Abstract][Full Text] [Related]
6. In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA' in a human acute myeloid leukemia xenograft tumor model.
Tur MK; Huhn M; Jost E; Thepen T; Brümmendorf TH; Barth S
Int J Cancer; 2011 Sep; 129(5):1277-82. PubMed ID: 21077160
[TBL] [Abstract][Full Text] [Related]
7. Target-specific cytotoxic activity of recombinant immunotoxin scFv(MUC1)-ETA on breast carcinoma cells and primary breast tumors.
Singh R; Samant U; Hyland S; Chaudhari PR; Wels WS; Bandyopadhyay D
Mol Cancer Ther; 2007 Feb; 6(2):562-9. PubMed ID: 17308054
[TBL] [Abstract][Full Text] [Related]
8. [Construction, expression and functional characterization of disulfide-stabilized anti-hepatocarcinoma single chain Fv fused with truncated Pseudomonas exotoxin].
Zhao J; Sun ZW; Liu YF; Yu WY
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2003 Nov; 19(6):585-7. PubMed ID: 15182657
[TBL] [Abstract][Full Text] [Related]
9. Bivalent disulfide-stabilized fragment variable immunotoxin directed against mesotheliomas and ovarian cancer.
Bera TK; Williams-Gould J; Beers R; Chowdhury P; Pastan I
Mol Cancer Ther; 2001 Dec; 1(2):79-84. PubMed ID: 12467225
[TBL] [Abstract][Full Text] [Related]
10. A recombinant immunotoxin engineered for increased stability by adding a disulfide bond has decreased immunogenicity.
Liu W; Onda M; Kim C; Xiang L; Weldon JE; Lee B; Pastan I
Protein Eng Des Sel; 2012 Jan; 25(1):1-6. PubMed ID: 22101015
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin.
Reiter Y; Kreitman RJ; Brinkmann U; Pastan I
Int J Cancer; 1994 Jul; 58(1):142-9. PubMed ID: 8014011
[TBL] [Abstract][Full Text] [Related]
12. Efficient targeting of CD13 on cancer cells by the immunotoxin scFv13-ETA' and the bispecific scFv [13xds16].
Grieger E; Gresch G; Niesen J; Woitok M; Barth S; Fischer R; Fendel R; Stein C
J Cancer Res Clin Oncol; 2017 Nov; 143(11):2159-2170. PubMed ID: 28669053
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of Resistance to Immunotoxins Containing
Dieffenbach M; Pastan I
Biomolecules; 2020 Jun; 10(7):. PubMed ID: 32630017
[TBL] [Abstract][Full Text] [Related]
14. Affitoxin--a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors.
Zielinski R; Lyakhov I; Jacobs A; Chertov O; Kramer-Marek G; Francella N; Stephen A; Fisher R; Blumenthal R; Capala J
J Immunother; 2009 Oct; 32(8):817-25. PubMed ID: 19752752
[TBL] [Abstract][Full Text] [Related]
15. Construction, expression, and activity of a novel immunotoxin comprising a humanized antiepidermal growth factor receptor scFv and modified Pseudomonas aeruginosa exotoxin A.
Akbari B; Farajnia S; Zarghami N; Mahdieh N; Rahmati M; Khosroshahi SA; Barzegar A; Rahbarnia L
Anticancer Drugs; 2017 Mar; 28(3):263-270. PubMed ID: 27861173
[TBL] [Abstract][Full Text] [Related]
16. Expression of VGRNb-PE immunotoxin in transplastomic lettuce (Lactuca sativa L.).
Mirzaee M; Jalali-Javaran M; Moieni A; Zeinali S; Behdani M
Plant Mol Biol; 2018 May; 97(1-2):103-112. PubMed ID: 29633168
[TBL] [Abstract][Full Text] [Related]
17. A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.
Weldon JE; Xiang L; Chertov O; Margulies I; Kreitman RJ; FitzGerald DJ; Pastan I
Blood; 2009 Apr; 113(16):3792-800. PubMed ID: 18988862
[TBL] [Abstract][Full Text] [Related]
18. Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer.
Baiz D; Hassan S; Choi YA; Flores A; Karpova Y; Yancey D; Pullikuth A; Sui G; Sadelain M; Debinski W; Kulik G
Neoplasia; 2013 Oct; 15(10):1172-83. PubMed ID: 24204196
[TBL] [Abstract][Full Text] [Related]
19. Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention.
Fleming BD; Urban DJ; Hall MD; Longerich T; Greten TF; Pastan I; Ho M
Hepatology; 2020 May; 71(5):1696-1711. PubMed ID: 31520528
[TBL] [Abstract][Full Text] [Related]
20. Soluble Cytoplasmic Expression and Purification of Immunotoxin HER2(scFv)-PE24B as a Maltose Binding Protein Fusion.
Park S; Nguyen MQ; Ta HKK; Nguyen MT; Lee G; Kim CJ; Jang YJ; Choe H
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
